A novel prostaglandin I₂ agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice.

ABSTRACT:

Background

ONO-1301 is a novel long-lasting prostaglandin (PG) I₂ mimetic with inhibitory activity on thromboxane (TX) A₂ synthase. This drug can also induce endogenous prostaglandin (PG)I2 and PGE2 levels. Furthermore, ONO-1301 acts as a cytokine inducer and can initiate tissue repair in a variety of diseases, such as pulmonary hypertension, pulmonary fibrosis, cardiac infarction, and obstructive nephropathy. In this study, our aim was to evaluate the effect of ONO-1301 on liver inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH).

Methods

The therapeutic effects of ONO-1301 against liver damage, fibrosis, and occurrence of liver tumors were evaluated using melanocortin 4 receptor-deficient (Mc4r-KO) NASH model mice. The e

SUBMITTER: Motegi S 

PROVIDER: S-EPMC8805395 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature